The glomerular filter: Biologic and genetic complexity  by Dandapani, S.V. & Pollak, M.R.
980   Kidney International (2006) 70
commentar y
see original article on page 1008
http://www.kidney-international.org
© 2006 International Society of Nephrology
The glomerular filter: Biologic and 
genetic complexity
SV Dandapani1 and MR Pollak1
The list of known genes that, when altered, cause proteinuric 
renal disease continues to increase. Recent mouse and human 
genetic studies, including that by Hasselbacher et al., are refocusing our 
attention on glomerular basement membrane components as critical to 
the barrier to protein filtration.
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Both the genetic and the biologic com-
plexity of the glomerular fi ltration bar-
rier have become increasingly apparent 
on the basis of a number of recent studies. 
Work over the past decade has provided 
tremendous insight into the most distal 
component of the glomerular fi lter, the 
podocyte. On the basis of a large number 
of genetic and cell biologic studies, we 
now know many of the proteins critical to 
the structure and function of the glomer-
ular slit-diaphragm complex of proteins 
as well as much about how many of these 
proteins function as structural and sign-
aling molecules.
However, a number of recent studies 
have refocused attention away from the 
podocyte’s structure and on its communi-
cation with other glomerular fi lter com-
ponents. Work in both mice and humans 
has refocused attention on the glomer-
ular endothelium. Systemic or local 
changes in vascular endothelial growth 
factor regulation can lead to signifi cant 
proteinuria and glomerular dysfunction 
as a result of its eff ect on this proximal 
component of the filter (reviewed by 
Eremina and Quaggin1). New studies 
are now redirecting our attention to the 
glomerular basement membrane (GBM) 
as a critical component of the barrier to 
protein fi ltration. Despite considerable 
new molecular and genetic data as well 
as a wealth of classical physiologic stud-
ies of the glomerular fi lter, the relative 
contributions of the three major compo-
nents, endothelium, GBM, and podocyte, 
are still debated.
Zenker et al. recently described a rare 
autosomal recessive condition defi ned 
by severe nephrosis presenting in early 
infancy accompanied by distinct ocu-
lar abnormalities.2 Th ey went on to use 
homozygosity mapping and candidate 
gene analysis to identify mutations in the 
laminin β2 gene, LAMB2, as the cause of 
disease in fi ve families with Pierson syn-
drome, named for the original describer.3 
Laminins are a critical component of the 
middle component of the GBM, the mid-
dle of the three structural components of 
this fi lter. Laminin β2 is part of a hetero-
trimeric complex of glycoproteins in the 
GBM, consisting of laminins α5, β2, and 
γ1 (Figure 1)4
Th e importance of LAMB2 in human 
glomerular function did not come as a 
surprise. In 1995, Noakes et al. demon-
strated that laminin β2 has a critical and 
non-redundant role in glomerular func-
tion: mice with a targeted deletion in the 
Lamb2 gene developed congenital neph-
rosis as well as neuromuscular disease.5 
Jarad et al. have now used this Lamb2–/– 
mouse model, with the extrarenal disease 
restored through use of a muscle-specifi c 
rat Lamb2 transgene, to help pinpoint the 
nature of the fi ltration defect in laminin 
β2 defi ciency.6 Despite severe congeni-
tal proteinuria, these mice show normal 
expression of the slit-diaphragm proteins 
nephrin and podocin and ultrastructurally 
normal-appearing podocyte foot proc-
esses. What makes the paper by Jarad et 
al.6 particularly interesting are the studies 
of GBM permeability using ferritin. Th e 
authors report a signifi cant increase in the 
permeability to ferritin that precedes and 
is independent of observable alterations in 
podocytes. By contrast, mice defi cient in 
the slit-diaphragm adaptor protein cd2ap, 
another model of nephrotic syndrome, 
showed normal distribution of ferritin 
into the GBM.
In a concise report in this issue of Kid-
ney International, Hasselbacher et al.7 
expand on these studies of laminin β1. 
Th ey examined six families with infants 
with congenital nephrotic syndrome, in 
which previous genetic studies had failed 
to fi nd defects in the known congeni-
tal nephrotic syndrome genes NPHS1 
(nephrin), NPHS2 (podocin), and WT1 
that explained disease. In two families, 
they identify LAMB2 mutations seg-
regating with disease. In one family in 
which both aff ected off spring haPollakd 
no evidence of ocular abnormalities, 
the aff ected members are homozygous 
for an R246Q missense amino acid sub-
stitution. In the second family reported, 
which exhibited milder ocular abnor-
malities than in the previous Pierson 
syndrome descriptions, the two aff ected 
children were found to be compound 
heterozygotes for N1380K and L1393F 
substitutions. Although functional 
changes in the encoded peptide are not 
documented, the evolutionary conser-
vation of the aff ected residues and the 
absence of these changes in control chro-
mosomes support the claim that these 
changes are responsible for the observed 
disease. They also illustrate a further 
form of genetic complexity: mutations 
in the same gene leading to different 
phenotypes. It is important not to over-
look the other signifi cant fi nding: in four 
of six families, LAMB2 mutations (and 
NPHS2, NPHS1, and WT1 mutations) 
do not explain disease, indicating that 
the spectrum of genetic lesions underly-
ing congenital nephrotic syndrome has 
yet to be fully defi ned.
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Together, these papers further expand 
and complicate our understanding of the 
glomerular fi lter and confi rm the impor-
tance of the GBM as a critical barrier to 
the fi ltration of protein. Th ese studies also 
point to areas in need of further study. 
How do the components of the fi ltration 
barrier communicate? Is an ultrastruc-
turally intact podocyte necessarily a 
normally functioning podocyte? Are 
secondary forms of proteinuric disease 
caused by dysregulation of any of these 
three filtration barrier components? 
Why is the phenotype associated with 
genetic alterations in related pathways 
so variable? For example, why do muta-
tions in type IV collagen cause X-linked 
or recessive Alport syndrome, with a 
renal disease characterized by hematu-
ria, sub-nephrotic proteinuria, and vis-
ible GBM changes, whereas mutations in 
laminin β2 cause an autosomal recessive 
renal disease characterized by congenital 
nephrosis? Th ere is a large spectrum of 
inherited proteinuric disorders, ranging 
from the relatively mild proteinuria and 
slowly progressive renal failure seen in 
individuals heterozygous for TRPC6 or 
ACTN4 mutations, to severe congenital 
nephrosis seen with NPHS1 (nephrin) or 
LAMB2 defects. Further work to defi ne 
the precise downstream eff ects of these 
mutant (or absent) proteins should help 
better explain this variability.
Although a good deal of the progress 
in understanding the molecular nature 
of the fi ltration barrier comes from stud-
ies of rare mendelian forms of disease, 
it is also interesting to think about the 
genetics and biology of proteinuria in 
the larger context of health and disease. 
A large body of data has made it clear 
that even mild proteinuria is a prog-
nostic indicator of poor cardiovascular 
outcome. It is less clear whether in this 
context proteinuria is a refl ection of sys-
temic vascular dysfunction, or whether 
dysfunction of the glomerular fi ltration 
barrier has a direct eff ect on the cardio-
vascular system.
Given that the pathways and genes 
involved in disease pathogenesis appear 
to be quite varied, we need to become 
better at describing and classifying the 
diseases we see in the clinic. For example, 
in clinical jargon, it is common to report 
that a patient ‘has FSGS’. However, focal 
segmental glomerulosclerosis (FSGS) is a 
form of injury seen on histologic exami-
nation, but certainly not a single disease 
entity. It would perhaps be better to say, 
for example, that a patient has nephrotic-
range proteinuria and an FSGS pattern 
of injury and harbors mutations in both 
the paternal and the maternal podocin 
allele. Certainly it is clear that knowing 
the molecular etiology of a glomerular 
lesion as well as its histologic appearance 
can be clinically useful. We now know 
that a significant fraction of children 
with steroid-unresponsive nephrotic syn-
drome have underlying podocin muta-
tions.8 Th ese children do not respond 
to steroid therapy and only rarely have 
recurrent disease in a renal allograft . As 
our understanding of other genetic eti-
ologies of nephrosis increases, so will 
our understanding of their prognostic 
and therapeutic implications.
So, how many underlying genetic 
defects can in fact cause congenital neph-
rosis? What proportion of congenital 
nephrosis is environmental, rather than 
genetic, in origin? How do environ-
mental factors interact with genetically 
triggered signals to produce (or reduce) 
proteinuria? Is the (sometimes neph-
rotic-range) proteinuria we see in diabe-
tes, HIV infection, and obesity mediated 
via the same biologic pathways that have 
been identifi ed through genetic studies 
of rare proteinuric diseases? Although 
both the biology and the genetics of the 
glomerular fi ltration barrier are becom-
ing increasingly complex, it seems clear 
that careful analyses of single-gene dis-
orders will continue to provide some of 
the most informative insights into dis-
ease mechanisms.
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Dialysis rationing in South Africa: 
A global message
JH Dirks1 and NW Levin2,3
Dialysis rationing resulting from limited facilities and health-care 
personnel in low- and middle-income countries such as South Africa 
must be addressed on several fronts. Prevention of kidney disease is 
an essential long-term approach, but in the short term, it is necessary 
to increase access to dialysis and transplantation, and to seek ways to 
limit the ‘brain drain’ to the developed world.
Kidney International (2006) 70, 982–984. doi:10.1038/sj.ki.5001798
Moosa and Kidd1 (this issue) have done 
the nephrology community a service in 
their article on the dangers of rationing 
dialysis treatment in a developing coun-
try. Th is well-documented paper puts on 
the table an array of issues for physicians 
who engage in renal replacement therapy 
(RRT) in low- and middle-income coun-
tries. It is also a challenge to those in the 
developed world, where over 80% of 
dialysis takes place, to heed the call. Th e 
paper describes the 25-year experience 
of the government-requested Western 
Cape Committee in South Africa, com-
posed of a renal-care team that decided 
whether patients presenting with end-
stage renal disease would be accepted 
or rejected for dialysis treatment. Some 
2500 patients were assessed. Those 
accepted were relatively more often 
white, under 40 years old, and likely 
transplantation candidates, had fewer 
complications, and were more often 
employed and married with dependents. 
Th ose rejected, and basically left  to die, 
had more complicated diseases, were 
relatively more oft en non-white, over 
40, and unemployed, lived further from 
the dialysis center, and were generally 
socially disadvantaged. Th e goal of the 
Western Cape Committee of 80 patients 
on dialysis was met, but the percentage 
accepted steadily decreased over time. 
In recent years there was also a signifi -
cant decrease in the number of patients 
receiving transplants.
Th e lack of health-care resources in 
low- and middle-income countries 
either makes RRT unavailable or forces 
life-and-death decisions by individual 
1Massey College, University of Toronto, Toronto, 
Canada; 2Albert Einstein College of Medicine, 
Bronx, New York, USA; and 3Renal Research 
Institute, New York, New York, USA
Correspondence: JH Dirks; President, The 
Gairdner Foundation; Senior Fellow, Massey 
College; 4 Devonshire Place, Toronto, Ontario M5S 
2E1, Canada. E-mail: john.dirks@utoronto.ca
committees formed for that purpose. 
It is true that the accepted patients, 
at least, are given an opportunity to 
receive quality RRT within a capped 
system, as exists in South Africa and 
indeed elsewhere. Decision making 
was compounded by systemic con-
straints, which included lack of fi nancial 
and human resources, late diagnosis of 
chronic kidney disease, other priorities 
(particularly HIV/AIDS), lack of basic 
amenities, the inaccessibility of rural 
populations, and a lack of government 
will to provide RRT. Interestingly, such 
decision-making committees seem to be 
less common at the present time.
Does rationing of health resources 
have a place in global society? In a 
national health-care system? Certainly 
in most countries, including South 
Africa, the fortunate few can turn to pri-
vate care if it is available. In a public sys-
tem one can understand the economic 
rationale for rationing, but as Moosa 
and Kidd1 point out, it is not likely to 
be a fair process.
Resources are a major issue world-
wide, and we must concede that hemo-
dialysis and peritoneal dialysis are 
expensive treatments, ranging from 
US$30 000 to $60 000 annually in 
developed countries2 and from $6000 
to $40 000 in developing countries.3 
In Ghana, for example, each session 
costs more than $100, which is far out 
of reach for most people. Can dialy-
sis be made more aff ordable? Has this 
question been adequately studied by 
the nephrology community? A group 
of International Society of Nephrology 
(ISN) dialysis physicians has met sev-
eral times to look at the components of 
dialysis cost. Broadly speaking, these 
include equipment and supplies, phar-
maceuticals, consumables, clean water, 
trained technicians and nurses, and gov-
ernment taxes.4 Some of these costs can 
be higher in the developing than in the 
developed world. Th e ISN group hopes 
to tailor an eff ective but less costly form 
of peritoneal dialysis and hemodialysis 
in developing countries by carrying out 
pilot studies and working together with 
government and industry to make dialy-
sis more available. Interestingly, in a few 
centers in India, dialysis costs have been 
